Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in MelanomaY.N. Vashisht Gopal, Michael A. Davies, Richard A. Scolyer et al.|Cancer Research|2014Cited by 205
A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600–Mutant Solid TumorsClinton Yam, Tara C. Gangadhar, Xiaowei Xu et al.|Clinical Cancer Research|2017Cited by 38
Supplementary Figures S1-S12 from Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in MelanomaY.N. Vashisht Gopal, Michael A. Davies, Helen Rizos et al.|Unknown|2023Cited by 0